about our portfolio
Portage has built a portfolio of five technology platforms initially yielding ten candidates that uniquely target different cancer resistance pathways.
We’re leading scientists and clinicians through the development of immunotherapies that augment responses in immunogenic tumors and help initiate a response in non-immunogenic tumors. The flagship platform within our portfolio is our invariant natural killer T-cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. Our portfolio also includes antibodies, small molecules and protein therapeutics delivered by novel intratumoral formulations (PORT-1), nanolipogels (PORT-4), and virus-like particles (PORT-5).